Home Overview Research Programs News & Outreach Technology Transfer About PHRI

 
Scientific Overview Research Interest Summary Principal Investigators    Yuri Bushkin, Ph.D.
   Neeraj Chauhan, Ph.D.
   Loren Day, Ph.D.
   Karl Drlica, Ph.D.
   David Dubnau, Ph.D.
   Marila Gennaro, M.D.
   Gilla Kaplan, Ph.D.
   Fred Kramer, Ph.D.
   Barry Kreiswirth, Ph.D.
   Leonard Mindich, Ph.D.
   Arkady Mustaev, Ph.D.
   Harvey Penefsky, Ph.D.
   David Perlin, Ph.D.
   Richard Pine, Ph.D.
   Abraham Pinter, Ph.D.
   Issar Smith, Ph.D.
   Patricia Soteropoulos, Ph.D.
   Sanjay Tyagi, Ph.D.
   David Wah, Ph.D.
   Chaoyang Xue, Ph.D.

   Research Faculty
   Eugenie Dubnau, Ph.D.
   Patricia Fontán, Ph.D.
   Jeanette Hahn, Ph.D.
   Salvatore Marras, Ph.D.
   Marcela Rodriguez, Ph.D.
   Lisa K. Ryan, Ph.D.
   Xilin Zhao, Ph.D.

Junior Faculty Members Research Grants
 
Karl Drlica, Ph.D.
 



Recent Articles

Epstein BJ, Gums JG, Drlica K. (2004).
The Changing Face of Antibiotic Prescribing: The Mutant Selection Window.
Ann Pharmacother. 2004 Aug 31 [Epub ahead of print]
PMID: 15340128

OBJECTIVE: To describe the mutant selection window, discuss supporting evidence and limitations, and suggest potential applications for clinical practice.

DATA SOURCES: A MEDLINE search (1990-December 2003) of the English-language literature was conducted using the key words antibiotic, antimicrobial, resistance, mutant, selection window, prevention, MPC, and MSW in various combinations. Original investigations and reviews evaluating the mutant selection window, including abstracts and proceedings, were considered for inclusion. Published articles were also cross-referenced, and experts were contacted to locate additional pertinent data.

STUDY SELECTION AND DATA EXTRACTION: All data sources identified were evaluated and all information deemed relevant was included.

DATA SYNTHESIS: Until recently, physicians have had few ways to preserve antimicrobials from resistance other than by prescribing the agents less often. The mutant selection window hypothesis may modify this paradigm by shifting the focus to dosing strategies that reduce the growth of resistant mutants. Conventional dosing strategies have been formulated on the likelihood of curing an individual patient. Unfortunately, doses that cure patients appear to enrich resistant subpopulations of bacteria, thus promoting resistance. Antimicrobial-pathogen combinations can be identified that minimize mutant selection and cure patients while possibly restricting the progression of resistance.

CONCLUSIONS: The mutant selection window hypothesis provides a framework for considering the contribution of dosing to resistance, and it offers ideas for restricting the enrichment of resistant mutants and antimicrobial resistance.



 
     Copyright © 2010 All rights reserved.   PHRI at ICPH 225 Warren St. Newark, NJ 07103-3535 TEL 973 854 3100, FAX 973 854 3101